Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
LGVN
#538
Longeveron Inc. Common Stock
0.973
5
USD
+20.33%
Sektor:
Gesundheitswesen
Basis:
USD
Gewinnwährung:
USD
Tagesspanne
Jahresspanne
Tagesänderung
+20.33%
Monatliche Änderung
+70.40%
6 month change
+70.40%
Jahresänderung
+70.40%
Vorheriger Schlusskurs
0.809
0
Open
0.973
5
Bid
0.973
5
Ask
0.976
5
Low
0.973
5
High
0.973
5
Volumen
14
Märkte
Aktien
Gesundheitswesen
LGVN
Open full chart
Financials
Overview
Finanzbericht
Statistics
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
532.65 K
616.3 K
1.03 M
13.47 M
—
Valuation ratios
Enterprise value
—
—
—
58.28 M
181.74 M
Price to earnings ratio
—
—
—
-0.66
14.36
Price to sales ratio
—
—
—
6 806.57
20.94 K
Price to cash flow ratio
—
—
—
1 174.02
2 967.23
Price to book ratio
—
—
—
743.88
1 108.52
Enterprise value to EBITDA ratio
—
—
—
-3.68
-10.35
Profitability ratios
Return on assets %
0.4
0.69
1.77
0.63
1.16
Return on equity %
0.46
0.92
3.18
0.73
1.6
Return on invested capital %
418.04
1 983.57
900.55
949.13
1 407.92
Gross margin %
45.18
40.67
31.17
78.76
297.35
Operating margin %
1 336.6
1 476.51
2 966.01
690.72
9 113.8
EBITDA margin %
-1 336.6
-1 476.51
-2 867.28
-661.45
-8 835.45
Net margin %
1 305.13
1 541.33
3 020.17
668.9
8 848.9
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
13.06
4.17
1.5
7.6
18.73
Inventory turnover
—
—
—
—
—
Asset turnover
0.03
0.03
0.04
0.13
0.06
Solvency ratios
Debt to assets ratio
0
0.08
—
—
—
Debt to equity ratio
0
0.11
—
—
—
Long term debt to total assets ratio
0
0.02
—
—
—
Long term debt to total equity ratio
0
0.03
—
—
—
Per share metrics
Operating cash flow per share
—
6.66
8.74
0
0
EBIT per share
—
-8.6
-9.68
-0
-0
EBITDA per share
—
-8.6
-9.35
-0
-0
Total debt per share
—
1.1
—
—
—
Cash per share
—
9.37
2.44
0
0
Net current asset value per share
—
9.67
2.69
0
0
Tangible book value per share
—
8.63
2.05
0
0
Working capital per share
—
7.35
0.9
0
0
Book value per share
—
9.78
3.1
0
0
Nachrichten
Longeveron schließt Finanzierung über 15 Mio. US-Dollar ab und sichert Betrieb bis Q4 2026
Longeveron closes $15 million financing, extends runway to 4Q26
Longeveron sichert sich bis zu 30 Mio. USD an frischem Kapital durch Privatplatzierung
Longeveron secures $15M financing, eyes $15M more on trial results
Longeveron veröffentlicht positive Phase-2b-Studienergebnisse zu Stammzelltherapie
Longeveron publishes phase 2b stem cell trial results in journal
Longeveron ernennt Stephen Willard vor entscheidenden Studienergebnissen zum neuen CEO
Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results
Longeveron receives Japanese patent for stem cell potency assay methods
Longeveron bereitet sich mit FDA-Meeting auf entscheidende Daten zur HLHS-Therapie vor
Longeveron prepares for pivotal HLHS therapy data with FDA meeting
Longeveron receives patent for stem cell therapy targeting female sexual dysfunction